Equities research analysts at Leerink Swann raised their price target on shares of Cadence Pharmaceuticals (NASDAQ: CADX)
Separately, analysts at Deutsche Bank reiterated an ?in-line? rating on shares of Cadence Pharmaceuticals in a research note to investors on Friday. They now have a $8.00 price target on the stock.
Four analysts have rated the stock with a buy rating, three have assigned a hold rating, and one has given an underweight rating to the company?s stock. The company presently has an average rating of ?overweight? and a consensus target price of $5.42.
Cadence Pharmaceuticals traded up 2.46% on Friday, hitting $5.42. Cadence Pharmaceuticals has a 1-year low of $2.56 and a 1-year high of $5.66. The stock?s 50-day moving average is currently $4.94. The company?s market cap is $463.7 million. Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates for use in the hospital setting.